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Human and simian immunodeficiency viruses infect
host lymphoid cells by binding CD4 molecules via their
gp160 envelope glycoproteins. Biochemical studies on
recombinant SIVmac32H (pJ5) envelope ectodomain
gp140 precursor protein show that the envelope is a
trimer. Using size exclusion chromatography, quantita-
tive amino acid analysis, analytical ultracentrifugation,
and CD4-based competition assay, we demonstrate that
the stoichiometry of CD4 receptor-oligomeric envelope
interaction is 1:1. By contrast, Fab fragments of both
neutralizing and non-neutralizing monoclonal antibod-
ies bind at a 3:1 ratio. Thus, despite displaying equiva-
lent CD4 binding sites on each of the three gp140 pro-
tomers within an uncleaved trimer, only one site binds
the soluble 4-domain human CD4 extracellular segment.
The anti-cooperativity and the faster koff of gp140 trim-
er:CD4 versus gp120 monomer:CD4 interaction suggest
that CD4-induced conformational change is impeded in
the intact envelope. The implications of these findings
for immunity against human immunodeficiency virus
and simian immunodeficiency virus are discussed.
The acquired immunodeficiency syndrome (AIDS)1 in hu-
mans and monkeys is caused, respectively, by the human im-
munodeficiency viruses (HIV1 and HIV2) and the related pri-
mate lentiviruses, designated simian immunodeficiency
viruses (SIVs) (1–7). Both HIV and SIV utilize CD4 molecules
as cellular receptors (8–13). Moreover, both viruses have a
related, trimeric envelope spike protein containing non-co-
valently associated gp120 and gp41 glycoprotein fragments
derived from a posttranslationally cleaved precursor polypep-
tide (14, 15). The envelope glycoproteins are essential for viral
infectivity and pathogenesis.
The HIV and SIV envelope trimers have at least three con-
formational states: an unliganded state found on the surface of
mature virions, a CD4-liganded state, and an end-product state
in which the gp120 fragments have dissociated from the gp41
trimers and the gp41 portions have rearranged (16–18). The
transition to this final state is triggered by binding of the viral
co-receptor, a member of the chemokine-receptor family (19,
20). There are likely to be intermediate states of varying sta-
bility in the transitions between the conformations just listed.
Cleavage of the envelope precursor (gp160) is required for the
transition between the last two states and may be important
for the first transition as well. CD4 binds more weakly to
envelope trimers from fresh viral isolates than to the gp120
monomers derived from them, consistent with the notion that
the initial state of the trimer restrains its gp120 moieties in a
low-affinity conformation and with the observations that CD4
binding induces a structural transition (21, 22).
Structures have been determined for the gp41 ectodomain, in
a state that probably corresponds to the final conformational
rearrangement (23–25) and for a truncated, monomeric HIV1
gp120 complexed with CD4 and a monoclonal Fab that covers the
co-receptor site (26). The latter structure is presumably also in a
state similar to the one found after dissociation of the gp120
fragment from the envelope trimer (16, 17). The structure of the
initial state of the gp160 (or gp120/gp41) trimer is not known.
Models derived from the structure of free gp120 in complex with
CD4 yield plausible approximations, but these are limited by
uncertainties concerning conformational rearrangements (27).
In this paper, experiments were designed to analyze proper-
ties of the SIVmac32H envelope protein ectodomain gp140,
overexpressed in a recombinant system. We have recently re-
ported results from chemical cross-linking, analytical ultracen-
trifugation, and mass spectrometry that demonstrate that the
secreted recombinant protein, modified to render it unsuscep-
tible to the processing cleavage, is a trimer (28). Stably trimeric
SIV envelope protein offers an opportunity to determine bio-
chemical correlates of its various states. We describe here the
kinetics of CD4 binding to trimeric gp140 versus monomeric
gp120 and the stoichiometry of the CD4 interaction for each.
We also report the binding properties of Fab fragments from
neutralizing and non-neutralizing monoclonal antibodies
(mAbs). We show that only one CD4 molecule binds to an
uncleaved trimer, while both neutralizing and non-neutraliz-
ing Fabs bind with a stoichiometry of one Fab per gp120/gp41
subunit.
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EXPERIMENTAL PROCEDURES
Expression and Purification of SIV gp140, gp140 Variants, gp120,
and Human CD4—SIV gp140 and variants from SIVmac32H (pJ5)
were expressed in Lec3.2.8.1 cells using the pEE14 expression system
as previously described and referred to as gp160e (28, 29). To produce
SIV gp120, the tissue plasminogen activator leader sequence was fused
with the N terminus of SIV gp120. SIV gp120 was amplified by polym-
erase chain reaction, gel purified, and cloned into pEE14 digested with
XbaI and EcoRI to generate pSG120 encoding amino acids 1–524. The
Lec3.2.8.1 supernatants containing gp140 were filtered (Corning, 0.22
m) and passed over a mAb 17A11 (30) affinity column (5-ml bed
volume) with a flow rate of 0.5 ml/min. The mAb 17A11 was coupled at
5 mg/ml to Gamma Bind Plus-Sepharose beads (Amersham Pharmacia
Biotech) via cross-linking with dimethyl pimelimidate. After extensive
washing with PBS, the bound gp140 protein was eluted with low pH
buffer (500 mM acetic acid, pH 3.0), and peak fractions were immedi-
ately adjusted to pH 7.2 using 1 M Tris, pH 9.0, pooled, concentrated to
2 ml with an Amicon Centriprep-50 concentrator, and loaded onto a
1.6  60-cm Superdex 200 column (Amersham Pharmacia Biotech)
equilibrated with 20 mM Tris, and 200 mM NaCl, pH 8.0. SIV gp140
(V1V2), gp140 (V1V2V3), gp140C1, gp140C2, and gp120 proteins
were purified following the same procedure. For purification of human
s4CD4, Chinese hamster ovary cell-secreted s4CD4 protein (31) was
purified using a 19Thy5D7 mAb affinity column chromatography and
then sized by a Superdex 75 gel filtration column equilibrated with 20
mM Hepes, and 100 mM NaCl, pH 7.0, to remove any aggregates. s2CD4,
an Escherichia coli protein comprising amino acids 1–183 of hCD4, was
produced, refolded, and purified as described (32).
Surface Plasmon Resonance Binding Analyses—All experiments
were performed with a BIACORE 1000 instrument (Biacore, Piscat-
away, NJ) at 25 °C in HBS running buffer (150 mM NaCl, 3.4 mM EDTA,
0.005% surfactant P-20, 10 mM Hepes, pH 7.4). For epitope mapping of
soluble gp140, the antigenic determinants recognized on the gp140
molecule in solution were mapped using a two-site assay. Each mAb
(0.6 M) was captured by RAM Fc covalently bound to the carboxylated
dextran matrix by an amine-coupling kit (Biacore) at a flow rate of 5
l/min. The unoccupied sites of RAM Fc were blocked with 5 l of an
unrelated mAb to avoid binding of the second mAb to unoccupied ligand
sites. In the two-step procedure, gp140 (0.2–2 M) was injected followed
by injection of the second mAb (0.6 M) at a flow rate of 5 l/min. For
determination of the mAb reactivity, mAbs were captured by RAM Fc
and then exposed to analyte containing gp140, gp140 (V1V2), gp140
(V1V2V3), or a chimeric HIV gp120-SIV gp41 fusion protein (kind gift
of George Gao, Children’s Hospital, Boston, MA). RAM Fc serves as a
convenient capture reagent for mAbs used in the kinetic experiments.
Analyte containing gp140 at eight different concentrations (5–300 nM)
was passed over each mAb surface. In parallel studies, s4CD4 was
added at a 20-fold molar excess to gp140 overnight before measuring
binding. Binding and dissociation were measured for 240 s each at a
flow rate of 50 l/min. The sensor surface was regenerated between
each binding reaction by using two washes of 0.1 M HCl for 15 s at 100
l/min.
For the kinetics of gp140 and gp120 binding to s4CD4, CD4 was
coupled to a CM5 chip surface using standard amine-coupling proce-
dures. The immobilization level was 500–1000 response units for
s4CD4. All experiments were performed on three surfaces of different
ligand densities in HBS buffer at 25 °C. Association was measured by
passing various concentrations of gp140 or gp120 (50 nM to 4 M) over
each ligand surface at a flow rate of 50–100 l/min. The sensor surface
was regenerated between each binding reaction by using two washes of
100 M HCl for 6 s at 100 l/min. Identical injections over blank
surfaces were subtracted from the data for kinetic data analysis. Bind-
ing kinetics were evaluated in a 1:1 binding model.
Stoichiometry Measurements—The protein concentrations of gp140
monomer, gp120, and s4CD4 were determined at 280 nm using the
theoretical extinction coefficients 181540 M1 cm1, 126250 M1 cm1
and 62060 M1 cm1, respectively, based on primary amino acid se-
quence. For the SIV envelope, this result was in excellent agreement
with the Bio-Rad version of the Bradford dye binding assay. For anal-
ysis of stoichiometry by gel filtration, purified trimeric gp140 was mixed
with Fab fragments at ratios from 1:1 to 1:5 (mol:mol). The protein
concentration of each of the two component mixtures prior to purifica-
tion ranged from 2–12 mg/ml. Each mixture was incubated overnight at
4 °C and subsequently analyzed by gel filtration using a Superdex 200
column equilibrated with 20 mM Tris-HCl, and 200 mM NaCl, pH 8.0, at
a flow rate of 0.7 ml/min controlled by the AKTA FPLC (Amersham
Pharmacia Biotech).
Neutralization Assay—All neutralization experiments were per-
formed with purified mAbs. SIVmac239 and SIVsmH-4 are molecularly
cloned viruses, whereas SIV/DeltaB670 and SIVmac251 (mac32H (pJ5)
equivalent) are uncloned virus stocks. Virus stocks were produced in H9
cells except for SIVmac239, which was produced in human peripheral
blood mononuclear cells. The SIVmac251 stock was extensively pas-
saged in T cell lines (33). Cell-free virus (50 l containing 0.5–1 ng of
p27) was added to multiple dilutions of mAbs in 100 l of growth
medium in triplicate wells of 96-well microdilution plates and incubated
at 37 °C for 30 min before addition of CEMx174 cells (105 cells in 100
l/well). Cell densities were reduced severalfold, and medium was re-
placed after 3 days of incubation. The incubation was continued until
virus-induced syncytium formation and cell killing were observed mi-
croscopically in wells incubated in the absence of mAbs. Neutralization
was measured by staining viable cells with Finter’s neutral red in
poly-L-lysine-coated plates. Neutral red uptake by CEMx174 cells is
linear from 3.1  104 to 5  105 viable cells/well corresponding to A540
values of 0.25–1.6. Percent protection was calculated by the difference
in absorption between test wells (cell plus mAb plus virus) and virus
control wells (cells plus virus), divided by the difference in absorption
between cell control wells (cells) and virus control wells. The ID50 is
defined as the concentration of mAb necessary to protect cells from
virus-induced death (to a level of 50%).
Amino Acid Analysis—For amino acid analysis (AAA), 200 g of
purified gp140 was incubated with s4CD4 to 30-fold molar excess over-
night at 4 °C and then loaded onto a Superdex 200 HR 10/30 column
controlled by an AKTA FPLC (Amersham Pharmacia Biotech). The
column was equilibrated with 20 mM Tris-HCl, and 200 mM NaCl, pH
8.0, at a flow rate of 0.7 ml/min. The peak fractions containing the
gp140-s4CD4 complex were separated from free s4CD4, pooled, concen-
trated, and buffer-exchanged into PBS for AAA. These samples as well
as purified gp140 alone and purified s4CD4 alone were individually
hydrolyzed under vacuum at 110 °C for 26 h in 0.2 ml 6 N HCl-1%
phenol. Norleucine was used as an internal standard. Calibration mix-
tures were used for quantification of unknowns. All samples were run in
triplicate. After hydrolysis, a K3EDTA extraction buffer was used to
transfer samples to an Applied Biosystems 420A derivatizer/analyzer.
Pre-column derivitization and ion exchange chromatography were used
to label and detect free amino acids. Samples were quantitated using
Rainin Dynamix data analysis and Microsoft Excel software.
Native Gel Analysis—For stoichiometric titration of 15E8 and other
Fab fragments against gp140 by native gel analysis, Fab fragments
were titrated against constant amounts of gp140 in various ratios from
1:1 to 1:5 (mol:mol), respectively. Each mixture was incubated over-
night at 4 °C and subsequently analyzed on gradient (4–15%) native
Phastgel using Phastsystem (Amersham Pharmacia Biotech). The in-
dividual components and the complex were visualized by Coomassie
Blue staining. The protein concentration of each of the two component
mixtures ranged from 4.8 to 13.6 mg/ml.
Immunoprecipitation of gp140-CD4 Complexes by OKT4—To inde-
pendently assess valency of CD4 binding to gp140, purified gp140 (400
g) was incubated with s2CD4 and s4CD4 at various concentrations
overnight at 4 °C. The molar ratio between gp140 and CD4 was main-
tained at 1:20. The gp140-CD4 complexes were purified on a Superdex
200 column equilibrated with PBS to remove unbound CD4 at 4 °C. The
purified gp140-CD4 complexes were then divided into two aliquots and
incubated with either anti-s4CD4-specific mAb OKT4 or KK41 anti-
envelope mAb (20 l of packed Sepharose beads coupled at 5 mg/ml of
mAb) for 2 h at 4 °C. Beads were washed five times with PBS including
0.1% Triton X-100 and analyzed on 12% SDS-PAGE.
Analytical Ultracentrifugation—Sedimentation equilibrium experi-
ments were performed using a Beckman XL-A analytical ultracentri-
fuge equipped with scanning absorbance optics for recording the protein
distribution. Three samples (each of 80 l volume, giving a sample
column height of 1.5–2 mm) were loaded into six-channel Yphantis-type
centerpieces with their corresponding buffer blanks (10 mM Tris HCl,
pH 8.0; 100 l volume). The An 60 Ti rotor used can accommodate three
cell assemblies, thus nine samples were examined during each analyt-
ical ultracentrifuge run. Thermodynamic equilibrium was attained at
rotor speeds of 20,000 and 24,000 rpm for CD4 and 6,000 rpm for gp140
and the CD4-gp140 mixtures. Equilibrium was ascertained by the sat-
isfactory overlay and subtraction of data acquired 3 h apart. A true
optical baseline free from macromolecular species was then obtained by
increasing the rotor speed to 40,000 or 47,000 rpm and recording a scan
after several hours.
The equilibrium data consist simply of the absorbance measured at
the selected scanning wavelength (in this case 282 nm for CD4 and 280
nm for gp140 and the CD4-gp140 mixtures) as a function of the radial
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position in the sample column. If the macromolecular system is consid-
ered to comprise self-interacting species the concentration at any radial
position in the sample column (ctotal(r)) is given by Equation 1 (34),
ctotal(r)  c  
i1
n





where c is proportional to the baseline absorbance; n is the total
number of species present in the self-association equilibrium; K1,i is the
equilibrium constant for the association of monomer to q(i)-mer; C1,0 is
the monomer concentration at the radial position of the first data point;
 is the reduced molecular weight ((M2(1-	
)/RT) where M is the
monomer mass;  is the rotor speed in radian/s; 	 is the partial specific
volume of the protein (ml/g); 
 is the solvent density (g/ml); R is the gas
constant (8.31432  107 erg/mol K); T is the absolute temperature (K));
 and 0 are the values of r
2/2 at any point r in the sample column and
at the radial position of the first data point respectively; B is the second
virial coefficient (here with units of inverse concentration); Ci(r) is the
concentration of the ith species at radial position r; q(i) is the degree of
association for the ith species. The second virial coefficient describes the
reduction in observed mass due to excluded volume and charge repul-
sion effects. For globular proteins with negligible net surface charge in
a solvent of finite salt concentration this term should be minimal.
The value of 	 for CD4 and gp140 was estimated from their known
amino acid sequences together with a contribution for glycosylation,
assuming that all potential glycosylation sites are fully occupied. This
gave 	  0.738 ml/g for CD4 and 0.700 ml/g for gp140. Regardless of the
ratio of mixtures (3:1, 2:1, or 1:1 in terms of monomers of CD4 per gp140
trimer) the weight average 	 of the system was calculated to be 0.710
ml/g. The method of Cohn and Edsall (35) and the consensus partial
specific volumes for the constituent amino acids reported by Perkins
(36) were used for the 	 calculations. The buffer density was calculated
(1.0009 g/ml) using the freeware program SEDNTERP (alpha.bbri.org/
rasmb/spin/ms_dos/sednterp-philo) (37). Equilibrium solute distribu-
tion data were analyzed with the Beckman XL-A data analysis soft-
ware, which uses a modified form of Equation 1.
RESULTS
SIV Envelope-Human CD4 Interaction—SIVmac32H gp140
envelope was produced in Lec3.2.8.1 cells using a glutamine
synthetase recombinant expression system. The latter Chinese
hamster ovary cell derivative secretes proteins with homoge-
neous N-linked glycan adducts (GlcNac2-Man5) but lacking
O-linked glycans. To prevent any dissociation of the gp120 from
the gp41 moiety, both primary and secondary protease cleavage
sites were eliminated by mutation of Arg-512 and Lys-523 to
glutamic acid residues. In so doing, the heterogeneity of SIV
protein could be minimized and the complexity of subsequent
analysis reduced as shown below. Additionally, variants of the
cleavage site-deficient gp140 precursor protein lacking V1 and
V2 loops (V1V2) or V1, V2, and V3 loops (V1V2V3) were
produced (28), as well as free gp120.
Fig. 1A represents a Superdex 200 gel filtration chromato-
gram of recombinant SIV envelope previously purified from
supernatants of Lec3.2.8.1 gp140 transfectants using a combi-
nation of 17A11 anti-SIV mAb affinity purification and gel
filtration. As shown, the trimeric SIV gp140 has an apparent
molecular mass of 440 kDa with Ve  10.32 ml. By 10%
SDS-PAGE analysis, a monomer band of 120 kDa is observed
for gp140 with slightly lower molecular masses of 103, 94, and
103 kDa for V1V2, V1V2V3, and gp120, respectively (Fig.
1A, inset). In contrast to the SIV gp140 precursor protein, in
which the cleavage sites have been eliminated, SIV gp140
protein containing a single intact cleavage site at Lys-523 (C1)
chromatographs as three peaks including aggregate, trimeric,
and monomeric components while SIV gp140 with both cleav-
age sites present (C2) is mostly a gp120 monomer by gel filtra-
tion (Fig. 1A, right panel margin).
Fig. 1B demonstrates that Lec3.2.8.1 cell-produced s4CD4
comprising amino acids 1–371 has a Ve  14.42 ml, consistent
with the molecular mass of 45 kDa observed under non-
reducing conditions in 12% SDS-PAGE. Note the slightly
slower mobility of the s4CD4 extracellular segment under re-
ducing relative to non-reducing conditions, consistent with dis-
ruption of intradomain disulfide bonds contributing to a less
compact structure. Fig. 1C shows that in the presence of a
30-fold molar excess of s4CD4, a complex of gp140-CD4 is
formed. This complexed envelope chromatographs slightly dif-
ferently from uncomplexed gp140 (Ve  10.17 ml versus Ve 
10.32 ml). 15% SDS-PAGE analysis of the complex followed by
Coomassie Blue staining (Fig. 1C, inset) indicates that the
intensity of the gp140 band is much greater than that of the
s4CD4 band, suggesting that the stoichiometry of s4CD4 bind-
ing to a given SIV trimer may not be 3:1 as predicted (27). In
contrast, comparable analysis of the monomeric SIV gp120-
FIG. 1. Gel filtration chromatography and SDS-PAGE analysis
of mac32H SIV gp140 and gp120 proteins and s4CD4. A, the SIV
gp140 glycoprotein purified by successive mAb 17A11 affinity chroma-
tography and gel filtration was analyzed on a Superdex 200 HR-30
column. Purified gp140, gp140V1V2, gp140V1V2V3, and gp120 pro-
teins were examined by 10% SDS-PAGE under reducing conditions
(inset). Superdex 200 chromatography of gp140 C1 and gp140 C2 pro-
teins are shown in the right margin. B, purified hs4CD4 protein derived
from Chinese hamster ovary cells was resized by Superdex 200 chro-
matography and analyzed by 12% SDS-PAGE under reducing (R) or
non-reducing (NR) conditions. C, purified gp140 was incubated with a
30-fold molar excess of s4CD4 overnight at 4 °C and then purified by
Superdex 200 chromatography. Peak fractions of the s4CD4-gp140 com-
plex were pooled and analyzed by 15% SDS-PAGE under reducing
conditions (inset) and compared with a s4CD4-gp120 complex formed
using a 5-fold molar s4CD4 excess (right margin). All SDS-PAGE gels
were stained with Coomassie Blue.
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CD4 complex shows the two components to be equivalently
stained (Fig. 1C, right panel margin). The chromatographic
behavior of the gp140-CD4 complex observed in Fig. 1C was
obtained with PBS as well as with 20 mM Tris, pH 8. In the
experiments, binding and column buffers were identical.
Binding Stoichiometry of s4CD4 and Anti-SIV gp140 Fabs to
SIV-gp140 Trimers—To examine more rigorously the binding
stoichiometry of CD4 and mAb anti-envelope Fab fragments to
SIV-gp140 trimers, we conducted a set of gel filtration studies.
Purified SIV gp140 was mixed at various ratios with s4CD4 or
15E8 Fab fragments employing conditions maximizing complex
formation, followed by Superdex 200 column chromatography.
As shown in Fig. 2A, uncomplexed gp140 chromatographs in
the expected position (Ve  10.32 ml). By contrast, 15E8 pre-
mixing with gp140 results in formation of a complex with
altered chromatographic behavior relative to the free trimer
such that Ve  10.09, 9.89, and 9.81 ml at 1:1, 1:2, and 1:3
gp140:15E8 ratios. Beyond the 1:3 ratio, Fab binding to gp140
is fully saturated. Hence, Ve at 1:3 and Ve at 1:5 are identical.
Note that at the highest concentration of 15E8, a readily de-
tectable peak of free Fab (Ve  16.25 ml) is evident. The small
but detectable amount of uncomplexed 15E8 Fab at lower ra-
tios of Fab to gp140 protein may be a consequence of dissocia-
tion of the Fab during the chromatography run, may indicate
that a fraction of the Fab is unable to bind to gp140, or may
result from minor inaccuracy of protein concentration determi-
nation. Analysis of 15E8 Fab binding to recombinant trimeric
envelope using a native gel mobility shift assay demonstrates
enlargement of the complex size as the ratio of gp140 to Fab is
changed from 1:1 to 1:2 to 1:3 with discernable excess Fab
evident in the Coomassie-stained gel at a greater than 1:3
gp140:15E8 ratio (data not shown). Thus, for the 15E8 Fab,
there is an equivalent binding epitope on the three protomers of
one SIV gp140 trimer. Consequently, the molar ratio of Fab:
trimeric envelope at saturation is 3:1.
The chromatographic behavior of the gp140-CD4 complex is
very different (Fig. 2B). At a 1:1 molar ratio of gp140 to CD4,
the trimer mobility shifts to Ve  10.17 ml relative to free
gp140. However, unlike with the Fab fragments, at gp140:CD4
ratios of 1:2 to 1:50 there is no increase in the relative molec-
ular weight of the formed complex, implying that only one
s4CD4 molecule is able to bind to trimeric gp140 in solution.
The sample of trimeric gp140 SIV envelope precursor contains
no free gp120; thus, the result is not due to shed envelope
monomer. Gel shift assays were also consistent with a 1:1
gp140:CD4 stoichiometry (data not shown).
Quantitative Amino Acid Analysis of CD4-SIV gp140 Com-
plexes—To confirm the 1:1 gp140:s4CD4 binding stoichiometry
indicated by both molecular sizing chromatography and native
gel electrophoresis, quantitative AAA was performed. SIV
gp140/s4CD4 protein complexes were generated in the pres-
ence of a 30-fold molar excess of s4CD4 and purified by Super-
dex 200 chromatography. Samples of these complexes as well
as purified SIV gp140 alone and purified s4CD4 alone were
individually hydrolyzed, and amino acids were quantified.
Three independent experimental data sets were obtained, and
the average results for leucine and lysine residues are provided
in Table I. Although all amino acid residues were analyzed,
these two are most informative because the contribution of CD4
in complex is large. For the gp140-CD4 complex, values are
given as the average number of residues at 1:1, 1:2, and 1:3
gp140:CD4 ratios in the designated columns as well as the
numbers of residues expected by AAA based on the average
number of residues of gp140 alone and s4CD4 alone at the
indicated stoichiometries. For example, at a 1:1 binding stoi-
chiometry, the quantities of leucine residues in the gp140-CD4
complex should be 163  50  213. However, based on actual
AAA, 199 leucine residues are observed, a 7% variance from the
theoretical value. Nonetheless, differences between observed
and expected values at 1:2 and 1:3 ratios are larger, 12 and
16%, respectively, consistent with the notion that the 1:1 bind-
ing stoichiometry is correct. Similarly, for lysine residues, 140
residues are observed compared with 138 (102  36) residues
predicted for the complex, a variance of 1%. Of the 17 amino
acid residues analyzed, 11 showed the least variance between
experimentally observed and expected values for the 1:1 bind-
ing stoichiometry. In contrast, only 2–3 residues were found
with least variance between observed and expected values at
1:2–1:3 gp140:CD4 ratios. For the 1:3 ratio data, the reliability
of the results is questionable given the low number of methi-
onines (five) in s4CD4. Cysteine residues were excluded from
consideration in view of the large variance. Collectively, these
data argue that the gp140:s4CD4 binding stoichiometry is 1:1.
The observed degree of variance between experimental and
predicted values is reasonable given potential incompleteness
of sample hydrolysis especially in view of the extensive glyco-
sylation of the gp140 moiety. Equivalent analysis utilizing the
two-domain s2CD4 E. coli protein also demonstrated a 1:1
binding ratio (Table I).
Evidence by Analytical Ultracentrifugation for a 1:1 Binding
Ratio of CD4 to gp140—Sedimentation equilibrium yielded
information on the stoichiometry of CD4 binding to trimeric
gp140 from determination of molecular masses of gp140-CD4
complexes that are independent of shape. The experiments
were performed using a Beckman XL-A analytical ultracentri-
fuge equipped with scanning absorbance optics for recording
the protein distribution. All data sets were initially fitted with
a model describing a single, thermodynamically ideal macro-
molecular solute species. In this way an estimate for the ap-
FIG. 2. Stoichiometry of gp140 complex formation with s4CD4
and 15E8 anti-gp140 Fab proteins. A, purified gp140 protein (200
g) was mixed with 15E8 Fab fragments in varying ratios ranging from
1:1 to 1:5 (mol:mol). B, purified gp140 (100 g) was mixed with s4CD4
in ratios ranging from 1:1 to 1:50 (mol:mol). Each of the above mixtures
was incubated overnight at 4 °C and subsequently analyzed by gel
filtration. Note that the gp140 alone (gp140:CD4  1:0) represents
200 g.
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parent whole-cell weight average molecular mass (Mw,app) was
obtained for each loading concentration of s4CD4, gp140, or the
mixture. These reduced data are plotted as a function of mono-
mer-loading concentration for s4CD4 and gp140 in Fig. 3.
Mw,app does not vary greatly with CD4 concentration nor with
rotor speed. Extrapolation of the two data sets to infinite dilu-
tion yields masses of 46.2  1.4 kDa and 44.0  0.8 kDa from
the 20,000 rpm and 24,000 rpm data, respectively (Fig. 3A).
Comparison of these values with the calculated monomer mass
for CD4 (43,942 Da) implies that CD4 is a monomer at the
concentrations studied. In addition to this, the solute distribu-
tions were well fit with the form of Equation 1 (see “Experi-
mental Procedures”) describing a thermodynamically ideal mo-
nomeric solute. The fits of the simplest form of the equation to
the solute distributions for gp140 were not as good as those
obtained for CD4; there was evidence for the presence of a
higher mass species near the base of the solute column. In Fig.
3B, Mw,app is plotted as a function of trimer concentration for
gp140; extrapolation of these reduced data to infinite dilution
gives M0  395.6  14.8 kDa. Trimeric gp140 would have a
mass of 331,350 Da (assuming full occupancy of the glycosyla-
tion sites). Thus, M0 implies the presence of a higher oligomer
(or aggregate). It was possible to obtain a marginal improve-
ment to some of the fits to the raw data using the form of
Equation 1, which describes a self-associating system, in par-
ticular a monomer-dimer system. In the case of gp140 “mono-
mer”, this is in fact a trimer-hexamer equilibrium. The disso-
ciation constants so obtained were small, averaging at 2.3 M
(on the gp140 trimer concentration scale). Thus, at the concen-
trations used in these studies, gp140 is mostly trimeric in
solution with the presence of a small amount of hexamer or a
small amount of aggregate.
Assuming that gp140 is largely trimeric, mixtures of s4CD4
and gp140 were prepared to examine three possible stoichiom-
etries of interaction: 3:1, 2:1, and 1:1 (s4CD4 monomer:gp140
trimer). Not surprisingly, suboptimal fits were obtained when
the thermodynamically ideal monomeric solute form of Equa-
tion 1 was used to fit the solute distributions acquired for these
mixtures. The values of Mw,app are, however, plotted as a func-
tion of s4CD4:gp140 stoichiometry in Fig. 3C. As shown, there
is little dependence of Mw,app upon total protein concentration
but very strong dependence on the stoichiometry of the
mixture.
To interpret the data summarized in Fig. 3C the whole-cell
weight-average mass was calculated for the three stoichiome-
try mixtures used depending on the mode of binding. This
calculation was made more complex by the possibility of gp140
existing in a trimer-hexamer equilibrium. However, the data in
Table II reveal that, irrespective of this possibility, the conclu-
sions remain the same. Across the table, the 1:1 association
model agrees most closely with the experimentally determined
values for Mw,app. Thus, according to sedimentation equilib-
rium studies, the mode of association between s4CD4 and
gp140 is 1 CD4 monomer per gp140 trimer.
Envelope Binding Competition Using s4CD4 and s2CD4 Pro-
teins and OKT4—It has been suggested that multimeric CD4
binding by HIV envelope protein oligomers is required for
gp120 dissociation as well as for viral adsorption and penetra-
tion (38, 39). In this regard, Earl et al. (40) previously pre-
sented data in favor of multimeric CD4 binding exhibited by
cell surface envelope proteins using an OKT4 coprecipitation
assay. To determine stoichiometry of CD4 binding, we adopted
this coprecipitation assay but using the purified soluble trim-
eric SIVmac32H gp140 precursor instead of detergent-soluble
envelope-expressing cell lysates. OKT4 recognizes s4CD4 but
not s2CD4. Thus, if trimeric gp140 proteins were incubated
with equimolar amounts of s4CD4 and s2CD4, OKT4 would
coprecipitate s2CD4 and gp140 in the case of multimeric CD4
binding to an envelope trimer. In contrast, neither free s2CD4
nor s2CD4 bound to gp140 should be immunoprecipitated un-
der these conditions if a single CD4 molecule binds to one
gp140 trimer. For this experiment, purified gp140 proteins
were incubated with s2CD4 and s4CD4 in various concentra-
tions at 4 °C overnight. CD4-gp140 complexes were subse-
quently purified by Superdex 75 column to remove unbound
CD4. The purified CD4-gp140 complexes were then divided
into two aliquots and immunoprecipitated with either the anti-
gp140 KK41 mAb or the anti-CD4 OKT4 mAb. As shown in Fig.
4, the amount of s4CD4 coprecipitated by anti-gp140 at various
s4CD4 concentrations was identical to the amount of s4CD4
immunoprecipitated by OKT4, indicating that only gp140-
bound s4CD4 remains after gel filtration and that little, if any,
dissociation of s4CD4 from gp140 occurs during immunopre-
cipitation. Furthermore, when gp140 proteins are incubated
with s4CD4 and s2CD4, anti-gp140 coprecipitates both s4CD4
and s2CD4 proteins (Fig. 4A) with a predictable stoichiometry
based on ratios of the input s4CD4 and s2CD4 proteins. On the
other hand, in contrast to anti-gp140, the OKT4 mAb immu-
noprecipitated only s4CD4, demonstrating that one CD4 mol-
ecule binds to each trimeric gp140. Our result is not in agree-
ment with multimeric CD4 binding observed by Earl et al. (40).
Possible explanations for this discrepancy may be that aggre-
gation of trimeric transmembrane envelope proteins during cell
lysis could result in coprecipitation of s2CD4 bound to one
envelope protein and s4CD4 bound to another envelope protein
molecule. Alternatively, nonspecific binding of gp140 to OKT4
may play a role in coprecipitation of s2CD4 bound to gp140
(Fig. 4B). Specific SIV and HIV trimers may also differ with
respect to anti-cooperativity observed (see below).
Kinetic Analysis of the s4CD4-gp140 and s4CD4-gp120 In-
TABLE I
Amino acid analysis of the CD4/gp140 complex indicates a 1:1 binding stoichiometry
Residues
Average number of residuesa Average number of residues/residues expected by AAA
b
(% variance gp140-CD4 complex)
gp140 alone CD4 alone 1:1c 1:2c 1:3c
gp140-s4CD4
Leu 163 50 199/213/(7%)d 230/263/(12%) 262/313/(16%)
Lys 102 36 140/138/(1%) 162/174/(7%) 184/210/(12%)
gp140-s2CD4
Leu 153 20 163/173/(5.7%) 177/193/(8.3%) 191/213/(10.3%)
Lys 106 18 125/124/(0.8%) 136/142/(4.4%) 146/160/(8.4%)
a Values of average calculated residues are based on three independent experimental data sets with mean values given. Standard deviations for
gp140 and CD4 residues were 0–8% and 3–8% for leu and lys, respectively.
b Values of residues expected by AAA are based on theoretical valency of binding (1:1, 1:2, or 1:3) using the avg. cal. res. from AAA determination.
c gp140-CD4 ratio.
d Numbers in parentheses represent variance between experimentally derived and theoretical values such that % variance  expected
residues  calculated residues/expected residues.
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teraction—Surface plasmon resonance was used to examine the
kinetics of the trimeric gp140-CD4 interaction and was com-
pared with that of monomeric gp120-CD4. To determine the
binding kinetics of trimeric gp140 to CD4, s4CD4 was immo-
bilized and gp140 protein passed over the chip surface in in-
creasing molar amounts. Representative kinetic data are
shown as sensorgrams in Fig. 5A. Data were fitted to a 1:1
binding model over the entire injection period. Kinetic data are
summarized for two independent experiments in Fig. 5C. The
Kd for gp140-CD4 interaction calculated from the ratio of koff:
kon ranges from 190–210 nM. A relatively slow kon is evident
(4.4–4.6  103 M1 s1). Fig. 5B shows data for monomeric
gp120 on the sCD4 surface. While the kon is similar, the koff is
3- to 4-fold slower, resulting in a longer t1/2 and a Kd 60 nM
(Fig. 5C). This Kd value lies between previously reported values
of 0.2–0.4 nM for the gp120 from SIVagm TYO-7 and 82–350 nM
for gp120 of SIVmac (41–43). Consistent with these data, tri-
mer-expressing virions of primary HIV-1 isolates have shown
resistance to soluble CD4 with lower affinity for CD4 binding
than that of recombinant monomeric gp120 (21).
Characterization of Anti-SIV Envelope mAbs That Neutralize
Viral Infection—Prior studies have suggested that viral neu-
tralization by an antibody is a function of its binding kinetics,
valency, epitope specificity, and/or binding site localization
(44–47). To investigate SIV neutralization, we utilized four
mAbs generated against virion-derived envelope as well as nine
mAbs generated against SIV mac32H gp140 protein. As shown
in Table III, of the mAbs tested, four (KK9, 17A11, 2C3, and
2C9) are potent at neutralizing the SIV mac251 strain (ID50 1
g/ml), one (9G3) is weakly neutralizing (ID50  9.51 g/ml),
and the remaining nine mAbs are without detectable activity
(ID50 50 g/ml). None of these mAbs cross-neutralize the
unrelated SIV strains 239, smH-4, or deltaB670. Mapping
studies, assessment of an epitope’s conformational versus lin-
ear character, kinetic antibody binding parameters, and va-
lency of interaction were examined.
Each of the mAbs whose Fab fragments were generated and
purified showed a stoichiometry of binding to the trimeric
gp140 envelope of 3:1 (Fig. 2 and data not shown). Hence,
valency per se is not a determinant of neutralization. As shown
in Table III, epitope mapping studies clearly localize a major
neutralizing epitope site: KK9, 17A11, 2C3, and 2C9 map to the
V3V4 region and cross-block each other’s binding. Among the
four mAbs, KK9 is most dependent on the V3 loop. Further-
more, none of the epitopes identified by these neutralizing
mAbs is detected in Western blots of denatured and reduced
gp140, implying that these mAbs, unlike the other nine mAbs,
recognize native conformational determinants (Table III and
data not shown). In contrast, the non-neutralizing 10B11 mAb,
which partially cross-blocks KK9 and localizes nearby to the V3
loop, identifies its epitope in Western blot analysis.
Kinetic analysis of mAb binding to trimeric gp140 shows that
kon varies from 3.5  10
4 to 9.3  106 M1 s1 with koff from
1.3–5.9  103 s1. Thus, the greatest determinant of affinity
is the kon, which varies by 200- to 300-fold for those mAbs.
While each of the four strongly neutralizing mAbs has a Kd 
2.3–4.1 nM, affinity as such is not the only determinant of
neutralization. The gp41-specific KK41 mAb, for example, pos-
sesses a Kd  2.1 nM with the fastest kon of the antibodies
tested (9.3  106 M1 s1) but is non-neutralizing. Additional
evidence comes from analysis of 9G3. This mAb, like KK41,
binds to gp41 and is partially overlapping with KK41 as shown
by cross-blocking studies. Nonetheless, 9G3 has neutralizing
activity whereas KK41 is non-neutralizing even though 9G3
TABLE II
Comparison of experimentally determined apparent whole cell weight average molecular mass with that calculated for different models of





b 413  7 378  9 346  10
No association between No (gp140)6
c 347 310 281
CD4 and gp140  (gp140)6
d 372 334 305
1:1 association No (gp140)6 441 394 356
(CD4:(gp140)3)  (gp140)6 432 388 353
3:1 association No (gp140)6 454 499 534
(CD43:(gp140)3)  (gp140)6 456 495 475
a Stoichiometry (CD4:gp1403).
b The average of the three data obtained with the three different total loading concentrations for each stoichiometric mixture.
c For this calculation, the presence of aggregate or hexameric gp140 was ignored and all gp140 was presumed to be in trimeric form.
d For this calculation, gp140 was presumed to exist in a trimer-hexamer equilibrium with Kd  2.32 M.
FIG. 3. Sedimentation equilibrium analysis of gp140/s4CD4 complexes. A, apparent whole cell weight average molecular mass plotted as
a function of monomer loading concentration for CD4. Data were acquired at rotor speeds of 20,000 rpm (E) and 24,000 rpm (). B, apparent whole
cell weight average apparent molecular mass plotted as a function of trimer-loading concentration for gp140. C), apparent whole cell weight
average apparent molecular mass plotted as a function of the stoichiometry of the CD4-gp140 mixture (as a molar ratio) for three different total
loading concentrations (0.5 M (E), 1.0 M (‚) and 1.5 M () CD4).
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affinity is slightly weaker than that of KK41 (Kd  3.7 versus
2.1 nM). Preincubation of gp140 with s4CD4 prior to mAb
binding, as described under “Experimental Procedures”, does
not alter the Kd of any of the mAbs by more than a factor of 2,
indicating that none of the mAbs recognizes an envelope
epitope whose conformation is affected in a major way by CD4
ligation. This does not exclude the possibility that such anti-
bodies exist, however.
DISCUSSION
Our finding that only one CD4 molecule can readily bind to
an SIV envelope trimer is unexpected. Nonetheless, this con-
clusion results from independent evaluations of gp140-CD4
complexes using molecular sizing chromatography, gel mobility
shift assays, quantitative amino acid analysis, and analytical
ultracentrifugation. Steric blockage of the two other potential
CD4 binding sites on a trimer by s4CD4 itself is an unlikely
explanation of the results because s2CD4, a truncated D1D2
envelope-binding fragment of CD4, also has the same binding
characteristics (Table I). How then can the observed stoichiom-
etry be rationalized?
The Fab binding analyses show that the trimer itself must be
a symmetric structure. None of the monoclonals in our panel,
which recognize epitopes distributed widely across the surface
of the molecule, appears to exhibit interference between related
sites on a trimer. By contrast, when CD4 binds, a striking
asymmetry is induced that effectively blocks the other two
sites. One potential source of this asymmetry is the constraint
imposed on the molecule by the intact cleavage site between
gp120 and gp41. When CD4 binds to one subunit in a trimer, it
induces a conformational change that transforms the target
gp120 into a conformation probably very close to the one seen in
the CD4/Fab/gp120-core complex studied by Kwong et al. (26).
If this change included displacements possible only if the C
terminus of gp120 and the N terminus of gp41 could move
relative to one another, then the changes induced in the un-
cleaved trimer would be incomplete and the trimer might ac-
commodate CD4 ligation by adopting an asymmetric structure.
The asymmetry would prevent the other subunits from under-
going a similar transition and thus would strongly reduce their
effective affinity for CD4.
An alternative hypothesis is that CD4 binding induces asym-
metry even in a cleaved gp140 trimer. CD4 binding to one
gp120 on a trimer clearly produces strain, since the affinity of
CD4 for gp120 on trimers is generally lower than its affinity for
free gp120 from the same viral isolate. The trimer adapts to
this imposed strain by shifting to a conformation that reveals a
co-receptor binding site but that is inherently less stable than
the “ground state”. Based on the kinetic analysis here, the
conformational adaptation of one gp120 subunit in a trimer is
not as favorable as of a gp120 monomer, hence yielding a faster
CD4 off rate for the former. If the conformational change in-
duced in the first subunit to bind produced sufficient strain in
FIG. 4. Evidence for binding of a
single CD4 molecule to trimeric
gp140 by biochemical analysis. Trim-
eric gp140 was incubated with s4CD4 and
s2CD4 at various concentrations at 4 °C
overnight, maintaining a 1:20 molar ratio
between gp140 and CD4. The gp140-CD4
complexes were subsequently purified on
a Superdex 200 column to remove un-
bound CD4. Equivalent amounts of
gp140-CD4 complexes were then incu-
bated with either anti-gp140 antibody
KK41 (A) or anti-s4CD4-specific antibody
OKT4 (B) and analyzed on 12% SDS-
PAGE stained with Coomassie Blue.
FIG. 5. Sensorgram overlays for
gp140 (A) and gp120 (B) binding to an
s4CD4 surface. Thin lines are fit to a 1:1
binding model. Solid lines represent ex-
perimental data. Concentrations of gp140
and gp120 analytes injected over the
s4CD4 surface are indicated. Residuals
are plotted below the sensorgrams. C,
summary of the kinetics of the s4CD4 in-
teraction with gp140 and gp120 proteins.
CD4-SIV gp140 Interaction Stoichiometry 42673
the neighbors to prevent symmetrical conformational changes
and hence, to block their capacity to bind CD4, we might expect
high concentrations of CD4 to induce gp120 dissociation (free-
ing it from the trimeric constraints and allowing it to open up
and bind CD4). CD4-induced shedding of gp120 has indeed
been described (48), but there are of course additional ways to
account for this observation.
Due to dissociation of gp120 from gp41, we have not suc-
ceeded in purification of an intact gp120-gp41 complex where
the two components are in noncovalent association. Hence, the
study of the stoichiometry of CD4 binding comparable with
that made with the non-cleavable gp140 precursor could not be
conducted. Furthermore, digestion of purified and uncleaved
gp140 C1 envelope protein in vitro by furin was not able to
generate gp120 and gp41 component products (data not
shown). Envelope glycosylation may protect the furin cleavage
site from digestion or additional enzymes may be required to
generate the mature envelope fragments.
Recently, Salzwedel and Berger (49) presented evidence for
cooperative subunit interaction within the oligomeric envelope
glycoprotein of HIV in the fusion process using a genetic
complementation analysis. By examining a series of envelope
variants with defects at specific functional sites in either gp120
or gp41 that render the glycoprotein incompetent for fusion
with a CD4 target cell bearing a particular co-receptor, they
showed that fusion can occur when one gp120 subunit is defec-
tive for CD4 binding or for co-receptor binding as long as it can
pair with a subunit with intact function. A similar result was
shown with complementation of normal and fusion-defective
gp41 components. These data are consistent with the notion
that binding of a single CD4 molecule to a trimeric envelope
protein is sufficient to trigger conformational change in the
native oligomer, subsequently followed by co-receptor binding
and fusion.
Whatever the detailed mechanism underlying the observed
anti-cooperativity of CD4 binding to trimeric gp140, we can
conclude that there must be a significant rearrangement in
gp120 on the surface of a trimer when it binds CD4, perhaps
including reorganization of the polypeptide chain near the
gp120/gp41 cleavage point. Binding of the Fabs analyzed here
appears not to induce this conformational change since we did
not observe comparable anti-cooperativity. In the event that
only the binding of a single CD4 molecule to a viral trimeric
gp160 spike is necessary to trigger conformational change lead-
ing to fusion, antibody-related viral neutralization would be at
a distinct disadvantage; blockade by a given antibody of all
three sites on the trimer is then required to prevent viral
binding and fusion.
Any of a number of theories have been proposed to explain
the basis upon which only certain antibodies neutralize vi-
ruses. Kinetic parameters including fast on rates and slow off
rates have been identified (44, 46). Others have emphasized
qualitative differences between neutralizing versus non-neu-
tralizing antibodies. For example, anti-envelope antibodies
that bind to the envelope spike on the virion will be neutraliz-
ing whereas those that bind to viral peptide fragments and/or
monomeric envelope components will fail to be neutralizing
(50). In the case of HIV1, it has been further suggested that
neutralization by antibody is determined primarily by occu-
pancy sites on the virion, regardless of epitope specificity (45).
The present findings speak to these issues in specific molec-
ular terms. Thus, while a threshold affinity is required for
neutralization, site-specific localization of epitope binding is
critical. For example, although KK41 binds SIV envelope with
a Kd  2.1 nM, equivalent to the neutralizing mAb 2C3 (2.3 nM),
the KK41 mAb is not neutralizing. This confirms other obser-
vations that certain mAbs and human anti-C4 mAbs bind well
to intact virions but do not neutralize the virus (51–53). More-
over, four of the five neutralizing antibodies identified here
recognize a native V3V4 conformational epitope as judged by
their inability to detectably bind to denatured gp140 in West-
ern blot analysis. These mAbs may directly or indirectly inter-
fere with chemokine receptor binding; such mAbs are known to
be neutralizing (30). These findings emphasize the view that
TABLE III
Characteristics of neutralizing vs. non-neutralizing anti-gp140 mAbs: epitope mapping and kinetics of binding





1 s1 s1 nM
KK19 virion V1V2 10H3  50 7.1  104 1.7  103 24 (18)
10H3 gp140 V1V2 KK19  50 6.5  105 1.4  103 21 (17)
KK9 virion V3 17A11,2C3,2C9  0.1–3.1 9.3  105 3.8  103 4.1 (8.0)
17A11 virion V3V4 KK9,2C3,2C9  0.21 5.6  105 1.5  103 2.8 (3.7)
2C3 gp140 V3V4 KK9,17A11,2C9  0.17 7.2  105 1.6  103 2.3 (2.5)
2C9 gp140 V3V4 KK9,17A11,2C3  0.32 3.9  105 1.4  103 3.5 (3.2)
10B11 gp140 V3 “plus” pKK9  50 3.9  104 2.2  103 56 (32)
13H10 gp140 unknown  50 3.5  104 2.0  103 59 (75)
15E8 gp140 unknown  50 1.0  105 1.9  103 19 (14)
116 V1V2V3 unknown  50 2.5  105 1.9  103 7.7 (8.0)
KK41 virion gp41 p9G3  50 9.3  106 1.9  103 2.1 (1.3)
9G3 gp140 gp41 pKK41  9.51 3.4  105 1.3  103 3.7 (5.3)
11D11 gp140 gp41  50 6.9  105 5.9  103 8.0 (7.7)
a mAbs are all of the IgG1 murine isotype.
b The immunogens for mAb production include virion related, a combination of recombinant vaccinia virus plus SIV-infected cells for KK19, KK9
and KK41 (66, 67) or SIV-infected cells alone (17A11) or a baculovirus produced mac32H (pJ5) gp140 for all the mAbs except 116 which utilized
the baculovirus produced gp140 V1V2V3 variant.
c Epitope mapping is based on reactivity binding profile and cross-blocking studies on BIAcore and prior studies (68, 69) mapping KK9 to V3 and
V4 regions. V3 “plus” designation for 10B11 is based on incomplete elimination of binding by the V1V2V3 mutation. gp41 specificity is based on
reactivity with chimeras ADA gp120-SIV gp41 fusion protein. V1V2 assignment was based on loss of antibody reactivity on V1V2 deleted gp140.
d Cross-blocking. Unless indicated, cross-blocking is complete. In the case of 10B11, KK41 and 9G3 cross-blocking is only partial (50%
inhibition), indicated by “p”.
e For Western blot, “” indicates that the mAb detects by Western blot gp140 run in SDS-PAGE under reducing conditions whereas “” indicates
no discernable reactivity.
f Neutralization assays were performed as described in “Materials and Methods” where values are expressed as ID50 (g/ml). For KK9 0.1–3.1
g/ml are reported (70). All other values are derived from the experiments herein where antibodies were tested in a minimum of two or more
separate experiments.
g Kinetics measurements are based on BIAcore data. All numbers in parentheses represent mAb binding to gp140 after the envelope has bound
s4CD4.
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most neutralizing antibodies recognize epitopes that contribute
to an accessible functional site on the native trimer structure of
the virion. Nevertheless, that non-conformational epitopes may
be neutralizing, at least under some circumstances, is evident
from the analysis of the gp41-specific 9G3 mAb. Consistent
with this finding is the observation that the broadly neutraliz-
ing antibody 2F5 recognizes a linear sequence epitope EL-
DKWA in the membrane proximal segment of HIV1-gp41 (54).
In the current study, we did not generate CD4 binding site-
specific mAbs. Kinetic data showed that the affinity of CD4 to
a gp140 trimer is weaker than that of CD4 to a gp120 monomer.
Perhaps the CD4 binding site is partially occluded by the
interactions between gp120 subunits in a trimer, necessitating
conformational alterations. The resistance of primary HIV-1
isolates to soluble CD4 therapy has been attributed to a lower
binding affinity of primary virus envelope glycoprotein oli-
gomers for CD4 (46, 55, 56). Although anti-CD4 mAb binding
site epitopes and the CD4 binding site overlap, mapping stud-
ies demonstrate that they are not identical (57). In the crystal
structure of the gp120-CD4-Fab complex, a number of the
residues contributing to CD4 binding site epitopes are located
in a depression at the interface between the inner and outer
gp120 domains, a configuration that may offer poor immuno-
genicity. Furthermore, CD4 binding site antibodies might rec-
ognize a native gp120 conformation that is altered in the CD4-
bound state (26). Dynamic alterations of the CD4 binding site
may foster poor antibody complementarity, resulting in only
modest antibody affinity for the site. Occlusion of the CD4
binding site epitopes by CD4 may delay the generation of high
affinity antibodies against the CD4 binding site epitopes.
Hence, CD4 binding site epitopes alone may not be sufficient
targets for vaccine development. Synergy between antibodies
directed against CD4 binding site epitopes and other unrelated
epitopes have been reported (58–61).
Elicitation of neutralizing antibodies by oligomeric forms of
soluble gp140 has been disappointing to date, perhaps because
those tested oligomers are mostly dimers or tetramers and
modified trimers (62–64). Nonetheless, recent comparison of
antibody responses in rabbits to HIV gp120 and gp140 pro-
duced and purified in an identical manner showed that gp140
elicits enhanced cross-reactivity with heterologous envelope
proteins as well as greater neutralization (65). Trimeric un-
cleaved gp140 produced as described here seems to be a phys-
iologic representation of the native envelope structure on the
virus particle and may offer a prototype for a useful immuno-
gen. The structure of the trimeric envelope glycoprotein in its
non-CD4 contacted ground state might provide the needed
clues for rational design of a protein fragment capable of elic-
iting neutralizing antibodies to the native molecule.
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